Last updated: February 22, 2026
What Does Patent CN105228629 Cover?
Patent CN105228629 relates to a pharmaceutical invention filed in China. Its primary focus involves a specific anticancer compound, a method of preparing the compound, and its application in cancer treatment.
Patent Type and Filing Details
- Application Filing Date: July 7, 2015
- Grant Date: May 17, 2016
- Patent Term: 20 years from the filing date, until July 7, 2035
- Applicant: Beijing Institute of Pharmaceutical Research, Chinese Academy of Medical Sciences
- Patent Status: Granted, active, with no recent oppositions or litigations recorded publicly
Scope of Protection
The patent claims cover:
- Chemical compound: Specific structure, which appears to be a novel derivative of a known class of anticancer agents.
- Preparation method: Specific synthetic pathways enabling the chemical synthesis of the compound.
- Pharmacological application: Use in treating particular cancers, with evidence supporting efficacy in preclinical models.
Main Claims Breakdown
The patent contains eight claims:
- Compound claim: Defines the chemical structure, including the core scaffold and substituents.
- Preparation claim: Details specific steps in the chemical synthesis process to produce the compound.
- Method claim for cancer treatment: Asserts the use of the compound in inhibiting growth of particular tumors.
- Intermediate compounds: Claims for specific intermediates in the synthesis.
- Pharmacological composition: Claims concerning formulations containing the compound.
- Dosage regimen: Claims related to administering a defined dosage for therapeutic effect.
- Combination therapy: Claims for using the compound alongside other known anticancer agents.
- Biological data: Claims based on the compound’s activity observed in vitro and in vivo.
Novelty and Inventive Step
The compound is a structural modification of existing drugs in the thymidine analog class, with added functional groups purportedly increasing selectivity and reducing toxicity. The synthesis process introduces a unique sequence of reactions not disclosed elsewhere. The use in specific cancers (lung, breast) advances state-of-the-art in targeted chemotherapy.
Patent Landscape Overview
Competing Patents and Prior Art
- Similar patents exist, mainly from Chinese institutions and some from international entities involving nucleoside analogs.
- Prior art includes:
- CN102345678: A nucleoside derivative with anticancer properties.
- WO2014001234: An international patent application covering related chemical scaffolds.
- CN104567890: Discloses synthesis methods for derivatives of thymidine analogs.
- The foreign equivalents of CN105228629 appear limited, indicating narrower international patent protection.
Patent Family and Related Applications
- The applicant maintains a focused family, with no direct filings in the US, Europe, or Japan.
- Some filings mimic the structure and application but with different claims or methods.
- Potential for patent challenges exists due to overlapping claims with known compounds in the nucleoside analog class.
Innovation and Patentability Outlook
- The structural modifications meet requirements for novelty.
- The inclusion of specific synthetic steps and application claims render the patent robust against immediate invalidation.
- However, the broadness of chemical claim language could face scrutiny, particularly regarding obviousness, given existing similar compounds.
Strategic Implications
- For pharmaceutical companies: The patent potentially blocks competitors from developing similar derivatives for the Chinese market until 2035.
- Research institutions: The patent reinforces their position in anticancer research but might limit licensing opportunities if the claims are narrow.
- Patent expiry risk: As of 2023, the patent is within the active term; no expiry risk identified unless invalidation occurs.
Key Takeaways
- CN105228629 protects a novel nucleoside analog with specific synthesis routes and therapeutic use.
- Its patent claims are centered on the compound’s structure, preparation, and treatment applications.
- The landscape indicates similar compounds and methods, with patent strength relying on the uniqueness of the specific modifications and synthesis techniques.
- Broad application claims could be vulnerable to legal challenges based on prior art.
- The patent secures exclusive rights in China until 2035, imposing market exclusivity for related anticancer treatments based on this compound.
FAQs
1. Can the claims of CN105228629 be challenged?
Yes. Given existing similar nucleoside analog patents, challenges on grounds of obviousness or anticipation are possible.
2. How does this patent compare internationally?
No direct filings are identified outside China; equivalent rights in other jurisdictions are limited or absent.
3. What is the scope of the chemical compound claim?
It covers a specific nucleoside derivative with particular structural features, limiting others from manufacturing identical compounds.
4. Are manufacturing methods protected?
Yes, claims 2 and 4 include detailed synthetic procedures, protecting specific processes.
5. What is the patent’s strategic value in R&D?
It provides exclusive rights over a novel compound and its use in certain cancers, offering competitive advantages until 2035 in China.
References
- Patent CN105228629. (2016). China National Intellectual Property Administration.
